147 related articles for article (PubMed ID: 33895063)
1. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Xie J; Li L
J Formos Med Assoc; 2021 Sep; 120(9):1796-1797. PubMed ID: 33895063
[No Abstract] [Full Text] [Related]
2. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Chiu YJ; Chen SC; Kang YN; Hou SK; Chao CC; Chang CC
J Formos Med Assoc; 2021 Apr; 120(4):1090-1099. PubMed ID: 33183879
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Rudin D; Kiss A; Wetz RV; Sottile VM
J Gastroenterol Hepatol; 2007 Jul; 22(7):977-83. PubMed ID: 17559376
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis.
Andriulli A; Leandro G; Niro G; Mangia A; Festa V; Gambassi G; Villani MR; Facciorusso D; Conoscitore P; Spirito F; De Maio G
Gastrointest Endosc; 2000 Jan; 51(1):1-7. PubMed ID: 10625786
[TBL] [Abstract][Full Text] [Related]
5. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
6. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
7. Post-ERCP pancreatitis.
Arata S; Takada T; Hirata K; Yoshida M; Mayumi T; Hirota M; Yokoe M; Hirota M; Kiriyama S; Sekimoto M; Amano H; Wada K; Kimura Y; Gabata T; Takeda K; Kataoka K; Ito T; Tanaka M
J Hepatobiliary Pancreat Sci; 2010 Jan; 17(1):70-8. PubMed ID: 20012323
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate.
Andriulli A; Solmi L; Loperfido S; Leo P; Festa V; Belmonte A; Spirito F; Silla M; Forte G; Terruzzi V; Marenco G; Ciliberto E; Sabatino A; Monica F; Magnolia MR; Perri F
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):713-8. PubMed ID: 15290665
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Yuhara H; Ogawa M; Kawaguchi Y; Igarashi M; Shimosegawa T; Mine T
J Gastroenterol; 2014 Mar; 49(3):388-99. PubMed ID: 23720090
[TBL] [Abstract][Full Text] [Related]
10. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
[TBL] [Abstract][Full Text] [Related]
11. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
12. Antiproteases in preventing post-ERCP acute pancreatitis.
Tsujino T; Kawabe T; Omata M
JOP; 2007 Jul; 8(4 Suppl):509-17. PubMed ID: 17625308
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
14. Does gabexate mesilate affect serum concentrations of acute phase proteins after endoscopic retrograde cholangiopancreatography examination?
Pezzilli R; Gabbrielli A; Labate AM; D'Alessio P; Barakat B; Costamagna G; Dibenedetti F; Massa M; Merlini G; d'Eril GM
Hepatogastroenterology; 2003; 50(51):851-5. PubMed ID: 12828103
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin bolus injection for post-ERCP pancreatitis prevention: a need for further study.
Rudin D
Gastrointest Endosc; 2008 Jan; 67(1):190; author reply 190-1. PubMed ID: 18155442
[No Abstract] [Full Text] [Related]
16. Prevention of post-ERCP pancreatitis.
Haber GB
Gastrointest Endosc; 2000 Jan; 51(1):100-3. PubMed ID: 10625814
[No Abstract] [Full Text] [Related]
17. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
18. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography.
Schneider J; Barkin J
Gastrointest Endosc; 1997 May; 45(5):447-8. PubMed ID: 9165340
[No Abstract] [Full Text] [Related]
19. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis.
Zhang ZF; Yang N; Zhao G; Zhu L; Zhu Y; Wang LX
Chin Med J (Engl); 2010 Sep; 123(18):2600-6. PubMed ID: 21034635
[TBL] [Abstract][Full Text] [Related]
20. [Can post-ERCP acute pancreatitis be predicted and prevented?].
Heyries L
Gastroenterol Clin Biol; 2001 Jan; 25(1 Suppl):1S241-6. PubMed ID: 11223596
[No Abstract] [Full Text] [Related]
[Next] [New Search]
